Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabo-Cemiplimab vs Cabozantinib in Advanced Adrenocortical Cancer
NCT06900595Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2026
- Primary completion
- Jun 2029
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab in adrenocortical carcinoma (ACC), sponsored by National Cancer Institute. Started Feb 2026; status: recruiting.
02
Drugs
cemiplimab
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT06900595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06900595.